The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs von van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., Voest, E. E.

Volltext

Guideposts on the journey to value von Schilsky, R.L.

Volltext

Optimizing Dosing of Oncology Drugs von Minasian, L, Rosen, O, Auclair, D, Rahman, A, Pazdur, R, Schilsky, R L

Volltext

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial von Rodon, J., Soria, J.C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J.J., Rubin, E., Onn, A., Schilsky, R.L., Miller, W.H., Eggermont, A.M., Mendelsohn, J., Lazar, V., Kurzrock, R.

Volltext

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials von VAN CUTSEM, E, HOFF, P. M, MARSHALL, J. L, MITCHELL, E. P, PEREZ-MANGA, G, ROUGIER, P, SCHMIEGEL, W, SCHOELMERICH, J, SOBRERO, A, SCHILSKY, R. L, HARPER, P, BUKOWSKI, R. M, CUNNINGHAM, D, DUFOUR, P, GRAEVEN, U, LOKICH, J, MADAJEWICZ, S, MAROUN, J. A

Volltext

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin von Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendrick, J., Maroun, J., Marshall, J., Osterwalder, B., Pérez-Manga, G., Rosso, R., Rougier, P., Schilsky, R. L.

Volltext

UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity von LYER, L, DAS, S, JANISCH, L, WEN, M, RAMIREZ, J, KARRISON, T, FLEMING, G. F, VOKES, E. E, SCHILSKY, R. L, RATAIN, M. J

Volltext

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer von Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., Cercek, A., Segal, N.H., Saltz, L., Varghese, A.M., Yaeger, R., Nusrat, M., Goldberg, Z., Ku, G.Y., El Dika, I., Margalit, O., Grinshpun, A., Kasi, P.M., Schilsky, R., Lutfi, A., Shacham-Shmueli, E., Khan Afghan, M., Weiss, L., Westphalen, C.B., Conca, V., Decker, B., Randon, G., Elez, E., Fakih, M., Schrock, A.B., Cremolini, C., Jayachandran, P., Overman, M.J., Lonardi, S., Pietrantonio, F.

Volltext

Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy von Hausheer, Frederick H., Schilsky, Richard L., Bain, Stacey, Berghorn, Elmer J., Lieberman, Frank

Volltext

Extrapolating data from clinical trials to real life: Estimating magnitude of clinical benefit in early breast cancer von Hudis, C, Schilsky, R, Miller, R

Volltext

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809 von Shapiro, C.L, Halabi, S, Hars, V, Archer, L, Weckstein, D, Kirshner, J, Sikov, W, Winer, E, Burstein, H.J, Hudis, C, Isaacs, C, Schilsky, R, Paskett, E

Volltext

Biological, clinical, and psychosocial correlates at the interface of cancer and aging research von Dale, William, Mohile, Supriya G, Eldadah, Basil A, Trimble, Edward L, Schilsky, Richard L, Cohen, Harvey J, Muss, Hyman B, Schmader, Kenneth E, Ferrell, Betty, Extermann, Martine, Nayfield, Susan G, Hurria, Arti

Volltext

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors von Desai, A. A., Schilsky, R. L., Young, A., Janisch, L., Stadler, W. M., Vogelzang, N. J., Cadden, S., Wright, J. A., Ratain, M. J.

Volltext

Improving evidence developed from population-level experience with targeted agents von McClellan, MB, Daniel, GW, Dickson, D, Perlmutter, J, Berger, DP, Miller, V, Nussbaum, S, Malin, J, Romine, MH, Schilsky, RL

Volltext

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine von Undevia, S. D., Kindler, H. L., Janisch, L., Olson, S. C., Schilsky, R. L., Vogelzang, N. J., Kimmel, K. A., Macek, T. A., Ratain, M. J.

Volltext

22 Success and pitfalls of targeted therapy combinations von Schilsky, R

Volltext

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 von ROSNER, G. L, HARGIS, J. B, HOLLIS, D. R, BUDMAN, D. R, WEISS, R. B, HENDERSON, I. C, SCHILSKY, R. L

Volltext

Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy von Venook, A., Niedzwiecki, D., Lenz, H., Mahoney, M., Innocenti, F., O'Neil, B., Hochster, H., Goldberg, R., Schilsky, R., Mayer, R., Polite, B., Atkins, J., Shaw, J.E., Bertagnolli, M., Blanke, C.

Volltext

The Oral Fluoropyrimidines in Cancer Chemotherapy von LAMONT, E. B, SCHILSKY, R. L

Volltext

Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer von Sargent, D J, Niedzwiecki, D, O'Connell, M J, Schilsky, R L

Volltext